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January 22, 2013:386–9with the ATRIA score correctly reclassified 4.7% (95% CI: 1.8 to
11.2; p  0.152) of the population, although this finding was
onsignificant.
In a Cox regression analysis, a HAS-BLED score 3 was a
redictor of major bleeding, any clinically relevant bleeding, and
eath, with hazard ratios of 2.3 (95% CI: 1.1 to 5; p  0.028), 2.7
95% CI: 1.9 to 3.8; p  0.001), and 2.8 (95% CI: 1.2 to 6.5; p 
.013), respectively (vs. low-risk category as baseline risk).
This is one of the first comparisons of bleeding risk–prediction
chemes in a cohort of nonwarfarin anticoagulated patients with
F. All 3 bleeding risk–prediction schemes demonstrated similar
odest discriminative performance for the outcome of major
leeding and death. HAS-BLED and HEMORR2HAGES dem-
onstrated superior discriminative performance compared with
ATRIA for the outcome of any clinically relevant bleeding.
Clinically relevant bleeding was the primary safety endpoint in
AMADEUS (which was centrally and blindly adjudicated) and would
be clinically meaningful and highly relevant to patients as well as to
clinicians who ultimately wish to assess, in everyday clinical practice,
those patients who are at risk of important bleeding events. The
modest predictive performance of the scores should be interpreted in
light of the low bleeding risk population in this clinical trial setting,
with the highest categorization into low risk (89.7%) seen for the
ATRIA score.
These results are in accordance with our observations in the
warfarin arm of the AMADEUS cohort (2), suggesting that
despite being initially validated in warfarin-treated populations,
the ATRIA, HAS-BLED, and HEMORR2HAGES schemes
etain their modest predictive performance in patients receiving
ther forms of (nonwarfarin) anticoagulation (1), and that the
AS-BLED and HEMORR2HAGES scores were clearly supe-
rior to the ATRIA score for the outcome of any clinically relevant
bleeding.
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Letters to the Editors
All CAD Is Not CHD,
and All CHD Is Not CAD
I read with great interest the review by Marzilli et al. (1) in a recent
issue of the Journal. The authors make a compelling case that
coronary artery disease (CAD) does not equal ischemic heart
disease (IHD), or vice versa. They also show that angina symptoms
do not always improve after coronary revascularization, whether
surgical- or catheter-based. Certainly every seasoned cardiologist
has seen patients who continue to have IHD symptoms despite
open “native artery” or “bypass graft.” However, many asymptom-
atic patients have received percutaneous coronary intervention
(PCI) or coronary artery bypass grafting (CABG) in the name of
obstructive CAD. Then, there are others who are asymptomatic
and have normal exercise tests despite bypass graft occlusion.
These observations support the essay by Marzilli et al. (1).
Unfortunately, our profession has become catheter laboratory
entric since the day we could see pictures of the live coronary
rtery. The advent of PCI has led to a new medical-industrial
nterprise in which administrators, hospitals, and physicians are
nthusiastic partners. So often one reads about greedy coronary
nterventionalists who have placed stents in arteries with minimal
esions or no lesions at all (2,3). These events have only served to
essen the public’s trust in physicians in general, and cardiologists
n particular. I feel a coronary intervention, such as a PCI, should
e performed only in patients with acute myocardial infarction,
nd CABG should be performed in patients with 2- or 3-vessel
isease with compromised left ventricular function.
We must realize that when we perform PCI or bypass surgery,
e create a new form of coronary lesion that is prone to rapid
therogenesis, and give another disease to the patient, that is,
oagulopathy, which is related to multiple antiplatelet and antico-
gulant drugs. Being true to ourselves and performing a procedure
hen it is needed is the correct, moral, and ethical approach. This
pproach will go a long way in controlling ever-rising healthcare
osts, and restore the public’s trust in their caregivers. The Institute
f Medicine has estimated that our country wastes $750 billion a
ear with inefficient utilization of resources, poor cost control, and
xcessive and unnecessary procedures (4). I urge all readers of the
ournal to read this report.
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Reply
We sincerely thank Dr. Mehta for his valuable comments on our
paper (1). We believe his considerations add important evidence to
our review, and hope this will further encourage the cardiology
community to contemplate old concepts with the challenging
attitude that obstructive coronary artery disease and ischemic heart
disease are not synonyms!
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and Cardiac Arrest in
Long-Distance Ski Races
We read with great interest the article by Hållmarker et al. (1)
egarding the incidence of cardiac arrest in Vasaloppet, the world’s
argest ski race, in which they report that coronary heart disease
as the cause for cardiac arrest in 80% of victims. Despite the fact
hat long-distance skiers are generally well-trained individuals,
xertional rhabdomyolysis and inflammation-induced prothrom-
otic changes during prolonged strenuous exercise may lead to
upture of previously silent coronary atherosclerotic plaque (2).
evertheless, exercising in cold weather, not only increases the risk
f acute cardiac events (3), but may also result in permanent airway
iseases.
Endurance skiers inhale large volumes of cold air during exercise
hile performing at 80% of their maximal oxygen consumption
nd have minute ventilations in excess of 100 l/min (4). This
esults not only in loss of water and heat from the lower respiratory
ract, but also in neutrophilic and lymphocytic bronchial inflam-
ation, epithelial damage, airway remodeling, and increased
irway hyper-responsiveness (5). Interestingly, Larsson et al. (6)
eported that asthma, asthma-like symptoms, and bronchial hyper-
esponsiveness are much more common in cross-country skiers
han in the general population and nonskiers. Repeated chronic
yperventilation can cause permanent bronchial disorders that may
nduce ventilatory limitations during intense ski races (7).
Occasionally, cardiac arrest in a person with asthma may be
udden and related to cardiac arrhythmias caused by hypoxia,
sphyxia due to severe bronchospasm and mucous plugging, or
ynamic hyperinflation that reduces venous return, blood pressure,
nd, eventually, coronary perfusion pressure, especially in dehy-
rated athletes with silent coronary artery disease (2,8). Of note,
exercise-induced bronchoconstriction may also occur in healthy
individuals without known asthma (9). Therefore, thorough pre-
participation screening and preventive measures to diminish expo-
sure of the airways to cold air should be instituted for all winter
sports athletes.
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